OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) - PROTEOSTASIS THERAPEUTICS IN ownership

PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 53 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q1 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.

Quarter-by-quarter ownership
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) ownership history of PROTEOSTASIS THERAPEUTICS IN
ValueSharesWeighting
Q4 2018$262,000,000
-61.9%
80,903
-31.4%
0.01%
-25.0%
Q4 2017$688,000,000
+450.4%
118,000
+806.6%
0.01%
+500.0%
Q1 2016$125,000,00013,0160.00%
Other shareholders
PROTEOSTASIS THERAPEUTICS IN shareholders Q1 2018
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 3,804,027$46,637,0006.29%
NEA Management Company, LLC 3,556,778$43,606,0001.73%
Opaleye Management Inc. 150,000$1,839,0001.08%
Rock Springs Capital Management LP 450,000$5,517,0000.37%
Hillhouse Capital Management 865,923$10,616,0000.24%
Eventide Asset Management 220,000$2,697,0000.18%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 186,000$2,280,0000.09%
Virtus ETF Advisers LLC 24,169$296,0000.09%
TFS CAPITAL LLC 20,078$246,0000.07%
Trexquant Investment LP 19,600$240,0000.04%
View complete list of PROTEOSTASIS THERAPEUTICS IN shareholders